Skip to main content
Log in

In silico drug discovery: Tools for bridging the NCE gap

  • Strategic Planning
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Abstract

The infrastructure is now in place for bioinformatics to launch drug discovery on a new growth curve.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: A number of pharmaceutical companies have set significant "stretch goals" for their R&D engine in order to generate an ongoing stream of NCEs and double–digit revenue growth rate.

References

  1. Drews, J. 1996.Nature Biotechnology 14:1516–1518.

    Article  CAS  Google Scholar 

  2. The Wilkerson Group recently completed the white paper "Assessment of Informatics Needs and Productivity Bottlenecks in Drug Discovery.".

Download references

Acknowledgements

We would like to acknowledge the help of Judy Korman and George Farrington, managing directors at The Wilkerson Group, for their comments and contributions to this article.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Larvol, B., Wilkerson, L. In silico drug discovery: Tools for bridging the NCE gap. Nat Biotechnol 16 (Suppl 1), 33–34 (1998). https://doi.org/10.1038/5412

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/5412

  • Springer Nature America, Inc.

This article is cited by

Navigation